Cambridge, UK-based Artios Pharma has appointed Dr Simon Boulton as vice president of science strategy.
Dr Boulton joins the newly-launched oncology specialist to lead the development of the company’s two lead DNA Damage Response (DDR) programmes as well as assisting the business development team in identifying new pipeline opportunities in the DDR sector.
He brings over 20 years of expertise in DNA repair and the treatment of cancer resulting from DNA damage to Artios Pharma, and currently serves as senior group leader at the Francis Crick Institute in London.
Dr Boulton is also an honorary professor at University College London, a fellow of the Academy of Medical Sciences and an elected member of the European Molecular Biology Organisation, from whom he won the EMBO gold medal for his work.
Dr Niall Martin, chief executive officer of Artios Pharma, said: “Following our recent successful £25m fundraise and subsequent launch of Artios as a new company focused on developing new DDR targeted cancer therapies, we are delighted to welcome Dr Simon Boulton to our management team.
“Simon brings with him considerable DDR experience and a wealth of contacts and knowledge in the field, all of which will be invaluable as we continue to build a pipeline of first-in-class DDR programmes and establish Artios as a leading player in the DRR field.”